Icosavax (Icosavax) Cash per Share : $4.58 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Icosavax Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Icosavax's Cash per Share for the quarter that ended in Sep. 2023 was $4.58.

Icosavax Cash per Share Historical Data

The historical data trend for Icosavax's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icosavax Cash per Share Chart

Icosavax Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash per Share

2.25

4.56

7.12

5.31

Icosavax Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash per Share	Get a 7-Day Free Trial											5.57	5.31	4.76	4.95	4.58

Icosavax Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Icosavax's Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	218.307	/	41.10
	=	5.31

Icosavax's Cash per Share for the quarter that ended in Sep. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	229.206	/	50.09
	=	4.58

Icosavax (NAS:ICVX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Icosavax Cash per Share Related Terms

Thank you for viewing the detailed overview of Icosavax's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Icosavax (Icosavax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Icosavax Inc (NAS:ICVX) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1930 Boren Avenue, Suite 1000, Seattle, WA, USA, 98101

Website

https://www.icosavax.com

Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.

Executives

Adam K. Simpson	director, officer: Chief Executive Officer	C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Niranjan Kanesa-thasan	officer: Chief Medical Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Cassia Cearley	officer: Chief Business Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Thomas Joseph Russo	officer: Chief Financial Officer	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032
Douglas Holtzman	officer: Chief Scientific Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Amin Khan	officer: EVP, Head of Research & Dev.	C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Elizabeth Bekiroglu	officer: See Remarks	1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793
Charles E Richardson	officer: See Remarks	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Jim Wassil	director	C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
John W. Shiver	director	C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102
Anofi	10 percent owner	46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017
Nanodimension Iii, L.p.	10 percent owner	GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807